Literature DB >> 29547966

Bayesian clinical trial design using historical data that inform the treatment effect.

Matthew A Psioda1, Joseph G Ibrahim1.   

Abstract

We consider the problem of Bayesian sample size determination for a clinical trial in the presence of historical data that inform the treatment effect. Our broadly applicable, simulation-based methodology provides a framework for calibrating the informativeness of a prior while simultaneously identifying the minimum sample size required for a new trial such that the overall design has appropriate power to detect a non-null treatment effect and reasonable type I error control. We develop a comprehensive strategy for eliciting null and alternative sampling prior distributions which are used to define Bayesian generalizations of the traditional notions of type I error control and power. Bayesian type I error control requires that a weighted-average type I error rate not exceed a prespecified threshold. We develop a procedure for generating an appropriately sized Bayesian hypothesis test using a simple partial-borrowing power prior which summarizes the fraction of information borrowed from the historical trial. We present results from simulation studies that demonstrate that a hypothesis test procedure based on this simple power prior is as efficient as those based on more complicated meta-analytic priors, such as normalized power priors or robust mixture priors, when all are held to precise type I error control requirements. We demonstrate our methodology using a real data set to design a follow-up clinical trial with time-to-event endpoint for an investigational treatment in high-risk melanoma.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Bayesian power; Clinical trial design; Power prior; Sample size determination; Sampling prior; Type I error rate

Mesh:

Year:  2019        PMID: 29547966      PMCID: PMC6587921          DOI: 10.1093/biostatistics/kxy009

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  13 in total

1.  Bayesian assessment of sample size for clinical trials of cost-effectiveness.

Authors:  A O'Hagan; J W Stevens
Journal:  Med Decis Making       Date:  2001 May-Jun       Impact factor: 2.583

2.  Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; H Amy Xia; Thomas Liu
Journal:  Biometrics       Date:  2011-09-28       Impact factor: 2.571

3.  Experience with reviewing Bayesian medical device trials.

Authors:  Gene Pennello; Laura Thompson
Journal:  J Biopharm Stat       Date:  2008       Impact factor: 1.051

Review 4.  The combination of randomized and historical controls in clinical trials.

Authors:  S J Pocock
Journal:  J Chronic Dis       Date:  1976-03

5.  Robust meta-analytic-predictive priors in clinical trials with historical control information.

Authors:  Heinz Schmidli; Sandro Gsteiger; Satrajit Roychoudhury; Anthony O'Hagan; David Spiegelhalter; Beat Neuenschwander
Journal:  Biometrics       Date:  2014-10-29       Impact factor: 2.571

6.  Projection from previous studies: a Bayesian and frequentist compromise.

Authors:  B W Brown; J Herson; E N Atkinson; M E Rozell
Journal:  Control Clin Trials       Date:  1987-03

7.  A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion.

Authors:  D J Spiegelhalter; L S Freedman
Journal:  Stat Med       Date:  1986 Jan-Feb       Impact factor: 2.373

8.  Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.

Authors:  Brian P Hobbs; Bradley P Carlin; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

9.  Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.

Authors:  Ming-Hui Chen; Joseph G Ibrahim; H Amy Xia; Thomas Liu; Violeta Hennessey
Journal:  Stat Med       Date:  2013-12-16       Impact factor: 2.373

10.  A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

Authors:  Haitao Pan; Ying Yuan; Jielai Xia
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2016-12-23       Impact factor: 1.864

View more
  11 in total

1.  Bayesian design of biosimilars clinical programs involving multiple therapeutic indications.

Authors:  Matthew A Psioda; Kuolung Hu; Yang Zhang; Jean Pan; Joseph G Ibrahim
Journal:  Biometrics       Date:  2019-11-11       Impact factor: 2.571

2.  BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data.

Authors:  Barry S Eggleston; Joseph G Ibrahim; Becky McNeil; Diane Catellier
Journal:  J Stat Softw       Date:  2021-11-30       Impact factor: 6.440

3.  Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.

Authors:  Janelle L Lennie; John T Mondick; Marc R Gastonguay
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-01-20       Impact factor: 2.745

4.  New approaches for testing non-inferiority for three-arm trials with Poisson distributed outcomes.

Authors:  Samiran Ghosh; Erina Paul; Shrabanti Chowdhury; Ram C Tiwari
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.899

5.  Revisiting a Null Hypothesis: Exploring the Parameters of Oligometastasis Treatment.

Authors:  Jessica A Scarborough; Martin C Tom; Michael W Kattan; Jacob G Scott
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-21       Impact factor: 8.013

6.  Bayesian design of clinical trials using joint models for longitudinal and time-to-event data.

Authors:  Jiawei Xu; Matthew A Psioda; Joseph G Ibrahim
Journal:  Biostatistics       Date:  2022-04-13       Impact factor: 5.279

7.  Power gains by using external information in clinical trials are typically not possible when requiring strict type I error control.

Authors:  Annette Kopp-Schneider; Silvia Calderazzo; Manuel Wiesenfarth
Journal:  Biom J       Date:  2019-07-02       Impact factor: 2.207

8.  Handling Poor Accrual in Pediatric Trials: A Simulation Study Using a Bayesian Approach.

Authors:  Danila Azzolina; Giulia Lorenzoni; Silvia Bressan; Liviana Da Dalt; Ileana Baldi; Dario Gregori
Journal:  Int J Environ Res Public Health       Date:  2021-02-21       Impact factor: 3.390

Review 9.  Prior Elicitation for Use in Clinical Trial Design and Analysis: A Literature Review.

Authors:  Danila Azzolina; Paola Berchialla; Dario Gregori; Ileana Baldi
Journal:  Int J Environ Res Public Health       Date:  2021-02-13       Impact factor: 3.390

10.  A decision-theoretic approach to Bayesian clinical trial design and evaluation of robustness to prior-data conflict.

Authors:  Silvia Calderazzo; Manuel Wiesenfarth; Annette Kopp-Schneider
Journal:  Biostatistics       Date:  2022-01-13       Impact factor: 5.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.